Relatively favorable outcomes of post-transplant pulmonary function in patients with chronic myeloid leukemia receiving non-myeloablative allogeneic hematopoietic stem cell transplantation
M. Y. Lee
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for more papers by this authorT. J. Chiou
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for more papers by this authorM. H. Yang
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for more papers by this authorL. Y. Bai
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for more papers by this authorL. T. Hsiao
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for more papers by this authorT. C. Chao
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for more papers by this authorS. L. Tung
Division of Medical Oncology, Department of Medicine, Ton-Yen Hospital, Hsin-chu, Taiwan
Search for more papers by this authorW. S. Wang
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for more papers by this authorC. C. Yen
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for more papers by this authorJ. H. Liu
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for more papers by this authorP. M. Chen
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for more papers by this authorM. Y. Lee
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for more papers by this authorT. J. Chiou
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for more papers by this authorM. H. Yang
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for more papers by this authorL. Y. Bai
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for more papers by this authorL. T. Hsiao
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for more papers by this authorT. C. Chao
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for more papers by this authorS. L. Tung
Division of Medical Oncology, Department of Medicine, Ton-Yen Hospital, Hsin-chu, Taiwan
Search for more papers by this authorW. S. Wang
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for more papers by this authorC. C. Yen
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for more papers by this authorJ. H. Liu
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for more papers by this authorP. M. Chen
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan
Search for more papers by this authorAbstract
Abstract: Pulmonary function tests were performed in 20 patients with chronic myeloid leukemia before and after human leukocyte antigen-matched allogeneic sibling hematopoietic stem cell transplantation (HSCT) to identify any conditioning treatment effects on post-transplant function from January 1995 to December 2002. Of 20 patients, eight received non-myeloablative conditioning treatment and 12 received conventional myeloablative conditioning treatment. Pulmonary function tests including forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), and diffusion capacity for carbon monoxide (DLCO) were performed pretransplant, 6 and 12 months post-transplant. Possible pre-HSCT and post-HSCT risk factors were evaluated for association with pulmonary function. The results showed that myeloablative conditioning treatment had greater negative impact on FEV1, FVC, and DLCO than non-myeloablative conditioning therapy. We conclude that non-myeloablative allogeneic HSCT may apply a better transplant choice in patients who need special concern with post-transplant pulmonary function changes.
References
- 1 Link H, Reinhard U, Blaurock M, Ostendorf P. Lung function changes after allogeneic bone marrow transplantation. Thorax 1986; 41: 508–512.
- 2 Sutedja TG, Apperley JF, Hughes JM, Aber VR, Kennedy HG, Nunn P, Jones L, Hopper L, Goldman JM. Pulmonary function after bone marrow transplantation for chronic myeloid leukemia. Thorax 1988; 43: 163–169.
- 3 Clark JG, Crawford SW, Madtes DK, Sullivan KM. Obstructive lung disease after allogeneic marrow transplantation. Ann Intern Med 1989; 111: 368–376.
- 4 Schwarer AP, Hughes JM, Trotman-Dickenson B, Krausz T, Goldman JM. A chronic pulmonary syndrome associated with graft-versus-host disease after allogeneic marrow transplantation. Transplantation 1992; 54: 1002–1008.
- 5 Socie G, Mary JY, Esperou H, et al. Health and functional status of adult recipients 1 year after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2001; 113: 194–201.
- 6 Marras TK, Szalai JP, Chan CK, Lipton JH, Messner HA, Laupacis A. Pulmonary functional abnormalities after allogeneic marrow transplantation: a systemic review and assessment of an existing predictive instrument. Bone Marrow Transplant 2002; 30: 599–607.
- 7 Chiou TJ, Tung SL, Wang WS, Tzeng WF, Yen CC, Fan FS, Liu JH, Chen PM. Pulmonary function changes in long-term survivors of chronic myelogenous leukemia after allogeneic bone marrow transplantation: a Taiwan experience. Cancer Invest 2002; 20: 880–888.
- 8
Chien JW,
Martin PJ,
Gooley TA,
Flowers ME,
Heckbert SR,
Nichols WG,
Clark JG.
Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation.
Am J Respir Crit Care Med
2003; 168: 208–214.
10.1164/rccm.200212-1468OC Google Scholar
- 9 Chien JW, Martin PJ, Flowers ME, Nichols WG, Clark JG. Implications of early airflow decline after myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 33: 759–764.
- 10 Rodriguez-Roisin R, Roca J, Granena A, Agusti AG, Marin P, Rozman C. Lung function in allogeneic bone marrow transplantation recipients. Eur Respir J 1989; 2: 359–365.
- 11 Prince DS, Wingard JR, Saral R, Santos GW, Wise RA. Longitudinal changes in pulmonary function following bone marrow transplantation. Chest 1989; 96: 301–306.
- 12 Tait RC, Burnett AK, Robertson AG, McNee S, Riyami BM, Carter R, Stevenson RD. Subclinical pulmonary function defects following autologous and allogeneic bone marrow transplantation: relationship to total body irradiation and graft-versus-host disease. Int J Radiat Oncol Biol Phys 1991; 20: 1219–1227.
- 13 Badier M, Guillot C, Delpierre S, Vanuxem P, Blaise D, Maraninchi D. Pulmonary function changes 100 days and one year after bone marrow transplantation. Bone Marrow Transplant 1993; 12: 457–461.
- 14 Curtis DJ, Smale A, Thien F, Schwarer AP, Szer J. Chronic airflow obstruction in long-term survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 16: 169–173.
- 15 Gore EM, Lawton CA, Ash RC, Lipchik RJ. Pulmonary function changes in long-term survivors of bone marrow transplantation. Int J Radiat Oncol Biol Phys 1996; 36: 67–75.
- 16 Clark JG, Schwartz DA, Flournoy N, Sullivan KM, Crawford SW, Thomas ED. Risk factors for airflow obstruction in recipients of bone marrow transplants. Ann Intern Med 1987; 107: 648–656.
- 17 Palmas A, Tefferi A, Myers JL, et al. Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantation. Br J Haematol 1998; 100: 680–687.
- 18 Slavin S, Morecki S, Weiss L, Shapira MY, Resnick I, Or R. Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy – from bench to patient bedside. Semin Oncol 2004; 31: 4–21.
- 19 Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S, Aker M, Naparstek E, Nagler A, Slavin S. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003; 101: 441–445.
- 20 Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998; 91: 756–763.
- 21 Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, Maris MB, Storb R. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756–762.
- 22 Yang MH, Chiou TJ, Chao TC, Hsiao LT, Chen PM. Delayed rejection after initial engraftment in non-myeloablative bone marrow transplantation. J Chin Med Assoc 2003; 66: 682–688.
- 23 Hung GY, Chiou TJ, Hsieh YL, Chen PM. Hwang B. Nonmyeloablative allogeneic bone marrow transplantation for orbital granulocytic sarcoma associated with t (8, 21) (q22;q22) in acute myeloid leukemia. Bone Marrow Transplant 2002; 29: 67–70.
- 24 Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS, Champlin RE, Vaughan WP. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000; 6: 548–554.
- 25 Andersson BS, Kashyap A, Gian V, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002; 8: 145–154.
- 26 Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED. Clinical manifestations of graft-vs-host disease in human recipients of marrow from HLA-matched-sibling donors. Transplantation 1974; 18: 295–304.
- 27 Koc S, Leisenring W, Flowers ME, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisolone versus prednisolone alone. Blood 2002; 100: 48–51.
- 28 Hsiao GM. The quality control and interpretation of spirometry. Thorac Med [Taiwan] 1995; 10: 190–200.
- 29 Maloney DG, Sandmaier BM, Mackinnon S, Shizuru JA. Non-myeloablative transplantation. Hematology (Am Soc Hematol Educ Program) 2002; 392–421.
- 30 Littler WA, Kay JM, Hasleton PS, Heath D. Busulphan lung. Thorax 1969; 24: 639–655.
- 31 Lund MB, Kongerud J, Brinch L, Evensen SA, Boe J. Decreased lung function in one year survivors of allogeneic bone marrow transplantation conditioned with high-dose busulphan and cyclophosphamide. Eur Respir J 1995; 8: 1269–1274.
- 32 Gore EM, Lawton CA, Ash RC, Lipchik RJ. Pulmonary function changes in long-term survivors of bone marrow transplantation. Int J Radiat Oncol Biol Phys 1996; 36: 67–75.
- 33 Della Volpe A, Ferreri AJ, Annaloro C, Mangili P, Rosso A, Calandrino R, Villa E, Lambertenghi-Deliliers G, Fiorino C. Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation. Int J Radiat Oncol Biol Phys 2002; 52: 483–488.
- 34 Couriel DR, Saliba RM, Giralt S, et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004; 10: 178–185.
- 35 Weisdorf D, Hakke R, Blazar B, Miller W, McGlave P, Ramsay N, Kersey J, Filipovich A. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991; 51: 1197–1203.
Citing Literature
